Clinical Practice Guidelines by Tumour Type

The ESMO Clinical Practice Guidelines (CPG) are intended to provide oncology professionals with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine.

Produced under the direction of the ESMO Guidelines Committee, each Clinical Practice Guideline includes information on the incidence of the malignancy, diagnostic criteria, staging of disease and risk assessment, treatment plans and follow-up designed to help oncologists deliver an appropriate quality of care to their patients.

The first of our 2017 Clinical Practice Guidelines is now online: Multiple Myeloma.

New ESMO Clinical Practice Guidelines

Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes, Acute Lymphoblastic Leukaemia, Extranodal Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma

Updated ESMO Clinical Practice Guidelines

Multiple Myeloma, Metastatic Non-Small-Cell Lung Cancer, Biliary Cancer, Gastric Cancer, Oesophageal Cancer, Renal Cell Carcinoma, Newly Diagnosed and Relapsed Follicular Lymphoma, Management of Febrile Neutropenia, MASCC and ESMO Consensus Guidelines for the Prevention of Chemotherapy and Radiotherapy-Induced Nausea and Vomiting